







October 01, 2022

To, Corporate Relations Department BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001.

Email Id: corp.relations@bseindia.com

Scrip Code: 540788 Security ID: ASPIRA

Subject: Disclosure in terms of Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 ("SAST Regulations")

Dear Sir/Madam,

Enclosed please find herewith declaration in Annexure-A in compliance of Regulation 29(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares & Takeover Regulations, 2011 with respect to the sale of shares.

This letter is intended for the information and records of the Target Company and the Stock Exchanges.

Thanking you,

Yours faithfully, For Yashraj Biotechnology Limited

Arvind Bhanushali (Authorised Signatory)

Encl: - as above

CC:- ASPIRA PATHLAB & DIAGNOSTICS LIMITED Flat NO.2, R.D. Shah Bldg, Shraddhanand Road Opp. Ghatkopar Railway Station, Ghatkopar (West) Mumbai - 400086

Registerd Address:

C232, TTC Industrial Area, MIDC, Navi Mumbai 400705

91-22-6216 6800

Correspondence Address:

C113, TTC Industrial Area, MIDC, Navi Mumbai 400705

91-22-6812 5300

MUMBA

## Annexure-A

## Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	ASPIRA PATHLAB & DIAGNOSTICS LIMITED		
Name(s) of the <del>acquirer</del> /seller and Persons Acting in Concert (PAC)with the <del>acquirer</del> /seller	Yashraj Biotechnology Limited		
Whether the acquirer/seller belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Before the acquisition/sale under consideration, holding of:	w same and same same		
a) Shares carrying voting rights	1435800	13.95	13.95
b) Shares in the nature of encumbrance (pledge/ lien/non-disposal undertaking/ others)	-	-	-
c) Voting rights (VR) otherwise than by shares	-	-	-
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carryingvoting rights in the T C (specify holding in each category)	-	-	-
e) Total (a+b+c+d)	1435800	13.95	13.95
Details of acquisition/sele	1000		
Details of acquisition/sale  a) Shares carrying no voting rights acquired/sold	1193626	12.00	12.00
b) VRs acquired /sold otherwise than by shares	-	-	-
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold		-	-
d) Shares encumbered / invoked/released by the acquirer	-	-	-
e) Total (a+b+c+/-d)	1193626	12.00	12.00



2,42,174	2.35			
	2.55	2.35		
-	-	-		
-	-	-		
The second secon	-	-		
2,42,174	2.35	2.35		
ic Open mar	ket			
29.09.2022	29.09.2022 – 30.09.2022			
aid 1,02,93,000	1,02,93,000 Equity shares of Rs.10 each			
aid 1,02,93,000	O Equity share	es of Rs.10 each		
1,02,93,000	1,02,93,000 Equity shares of Rs.10 each			
	2,42,174 ic Open mar 29.09.2022 aid 1,02,93,000	2,42,174 2.35  ic Open market 29.09.2022 – 30.09.202  aid 1,02,93,000 Equity share		

- (\*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.
- (\*\*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Signature of the Authorised Signatory

Arvind Bhanushali

Place: Mumbai Date: 01.10.2022